AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
Log in

NASDAQ:ALDRAlder Biopharmaceuticals Price Target & Analyst Ratings

Notice: This company has been marked as potentially delisted and may not be actively trading.
$18.88
0.00 (0.00 %)
(As of 10/22/2019)
Add
Compare
Today's Range
$18.88
Now: $18.88
$18.88
50-Day Range
$18.88
MA: $18.88
$18.88
52-Week Range
$8.39
Now: $18.88
$19.12
VolumeN/A
Average Volume5.12 million shs
Market Capitalization$1.58 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.64

Analyst Ratings

Alder Biopharmaceuticals (NASDAQ:ALDR) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Alder Biopharmaceuticals in the last 12 months. Their average twelve-month price target is $18.90, suggesting that the stock has a possible upside of 0.11%. The high price target for ALDR is $20.00 and the low price target for ALDR is $18.00. There are currently 8 hold ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.102.10
Ratings Breakdown: 0 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
9 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
9 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.90$18.90$18.07$18.07
Price Target Upside: 0.11% upside0.11% upside4.28% downside4.28% downside

Alder Biopharmaceuticals (NASDAQ:ALDR) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Alder Biopharmaceuticals (NASDAQ:ALDR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/22/2019MizuhoReiterated RatingHold$18.00Low
9/17/2019Credit Suisse GroupReiterated RatingNeutral$11.00 ➝ $19.00Low
9/17/2019UBS GroupUpgradeSell ➝ Neutral$9.00 ➝ $19.50Low
9/16/2019SVB LeerinkDowngradeOutperform ➝ Market PerformLow
9/16/2019Morgan StanleyUpgradeUnderweight ➝ Equal Weight$15.00 ➝ $18.00Low
9/16/2019Needham & Company LLCDowngradeBuy ➝ HoldLow
9/16/2019Canaccord GenuityDowngradeBuy ➝ Hold$20.00Low
9/16/2019BMO Capital MarketsDowngradeOutperform ➝ Market PerformHigh
5/3/2019CowenSet Price TargetBuy$18.00Low
5/2/2019Cantor FitzgeraldReiterated RatingHold$14.00High
11/6/2018Wells Fargo & CoInitiated CoverageOutperformMedium
8/7/2018Stifel NicolausInitiated CoverageBuy$30.00Low
8/6/2018Piper Jaffray CompaniesInitiated CoverageOverweight$28.00Low
4/24/2018Goldman Sachs GroupInitiated CoverageNeutral$17.00High
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$17.00High
7/5/2017AegisReiterated RatingBuy$41.00Low
(Data available from 7/2/2018 forward)
This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.